Page 6 - Disease Modifying Drugs and Family Planning in MS

EXPERT CONSENSUS RECOMMENDATIONS ON THE USE OF INDIVIDUAL
DMDS IN WOMEN PLANNING A PREGNANCY ACCORDING TO DISEASE ACTIVITY

Most DMDs should be discontinued immediately on discovering a pregnancy. Where active
treatment must be maintained, bridging between prior and subsequent higher activity DMDs
with interferon may be an option.

Patient with active MS Patient with highly active MS

High consensus High consensus

Interferon ß Cladribine tablets

Glatiramer acetate Natalizumab

Ocrelizumab

Moderate consensus Moderate consensus

Dimethyl fumarate Alemtuzumab

Cladribine tablets

Low consensus Low consensus

Natalizumab Dimethyl fumarate

Ocrelizumab

Consensus levels were as follows: high, 8 or more physicians; moderate, 4–7 physicians; low, 1–3 physicians

6

GULF-NONNI-00004